A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

Obesity and diabetes companies soared this year, while the rest of pharma did poorly

Related Keywords

Eli Lilly ,Novo Nordisk ,Charlotte De La Fuente ,Wall Street ,Pharmaceutical Index ,Wsjfinance ,Wsjfinance Markets ,Pharmaceuticals ,Cancer Drugs ,Healthcare Life Sciences ,Specialized Drugs Medications ,Corporate Industrial News ,Cancer ,Political General News ,Society Community ,Diabetes ,Health ,Medical Conditions ,Obesity ,Social Issues ,Synd ,Wsj Pro Com ,Rally ,Abbvie ,Abbv ,Bristol Myers Squibb ,Bmy ,Gilead Sciences ,Gild ,Johnson Amp ,Jnj ,Novob Ko ,Dk Novo B ,Pfizer ,Pfe ,Novartis ,Novn Eb ,Ch Novn ,Astrazeneca ,Azn Ln ,Uk Azn ,Link I1 Wp Wsj 0001456008 ,Link I7 Wp Wsj 0001456008 ,Link I2 Wp Wsj 0001456008 ,Link I4 Wp Wsj 0001456008 ,Link I5 Wp Wsj 0001456008 ,Link I3 Wp Wsj 0001456008 ,Corporate ,Industrial News ,Political ,General News ,Society ,Community ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,